加载中
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
常规交易时段
US$3.035
−US$0.095 · -3.04%
盘中时间采用ET。市场数据可能有所延迟。
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
日内区间
当前US$3.035
52周区间
当前US$3.035
盘中时间采用ET。市场数据可能有所延迟。
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
日内区间
当前US$3.035
52周区间
当前US$3.035
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 3.49亿 USD | 2.86亿 USD | 1.99亿 USD | 9977万 USD | 7544.2万 USD |
| 销货成本 | 6116万 USD | 7660.2万 USD | 6277.1万 USD | 5749.7万 USD | 3885.7万 USD |
| 毛利 | 2.88亿 USD | 2.09亿 USD | 1.36亿 USD | 4227.3万 USD | 3658.5万 USD |
| 研究与开发 | 6634.8万 USD | 4589.3万 USD | 3128.3万 USD | 1972.1万 USD | 1231.2万 USD |
| 销售、一般及管理费用 | 1.44亿 USD | 9432.9万 USD | 9431.4万 USD | 9147.3万 USD | 7741.7万 USD |
| 营业费用 | 2.49亿 USD | 1.36亿 USD | 1.28亿 USD | 1.06亿 USD | 8360.7万 USD |
| 利息收入 | — | 1261.5万 USD | 615.4万 USD | 251.3万 USD | 11.2万 USD |
| 利息支出 | 1383万 USD | 3798.1万 USD | 2516.1万 USD | 2476.9万 USD | 1657.7万 USD |
| 折旧和摊销 | 1228.4万 USD | 896.8万 USD | 580.1万 USD | 631.2万 USD | 324.4万 USD |
| 营业利润 | 3880.1万 USD | 7258.7万 USD | 867.8万 USD | −6411万 USD | −4702.2万 USD |
| 净利润 | 586.3万 USD | 2758.8万 USD | −1193.8万 USD | −8740万 USD | −8092.6万 USD |
公司数据更新于 2026年10月13日。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$10.00
上涨空间 229.49%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI3740.26万0.00%2.3万亿 USD0.03%US$381.13-0.12%
iShares Russell 2000 ETFIWM2537.96万0.03%787.4亿 USD0.19%US$276.3-0.58%
State Street SPDR S&P Biotech ETFXBI2339.3万0.23%103.03亿 USD0.35%US$148.19-2.12%
Vanguard Extended Market ETFVXF1436.5万0.01%954亿 USD0.05%US$232.07-0.62%
iShares Russell 2000 Growth ETFIWO919.61万0.07%139.17亿 USD0.24%US$351.25-0.70%
iShares Biotechnology ETFIBB748.62万0.07%108.2亿 USD0.44%US$200.99-1.60%
Vanguard Russell 2000 ETFVTWO709.04万0.04%180亿 USD0.06%US$111.6-0.60%
First Trust Small Cap Growth AlphaDEX FundFYC556.18万0.41%13.49亿 USD0.70%US$114.28-0.49%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOFirst Trust Small Cap Growth AlphaDEX FundFYCAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
